ABL501, PD-L1 x LAG-3, a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1.

被引：2

作者：

Park, Eunyoung ^{[1
]}

Kim, Hyunejoo ^{[1
]}

Sung, Eunsil ^{[1
]}

Jung, Uijung ^{[1
]}

Hong, Youngeun ^{[1
]}

Lee, Hanbyul ^{[1
]}

Ko, Minkyung ^{[2
]}

Park, Yoon ^{[2
]}

Park, Chan Kwon ^{[3
]}

Kim, Seung Joon ^{[3
]}

Yoo, Jongman ^{[4
]}

Lee, Kyung Jin ^{[5
]}

Kim, Jihyo ^{[5
]}

Lee, Bo Eun ^{[5
]}

Won, Jonghwa ^{[1
]}

Jung, Jaeho ^{[1
]}

机构：

[1] ABL Bio INC, Seongnam, South Korea

[2] Korea Inst Sci & Technol, Seoul, South Korea

[3] Catholic Univ Korea, Seoul, South Korea

[4] CHA Univ, Sch Med, Seongnam, South Korea

[5] ORGANOIDSCIENCES LTD, Seongnam, South Korea

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1633

引用

页数：2